US EditionFDA Approves First Daily Pill for Weight Loss Treatment
The FDA approved the first daily oral GLP-1 drug for obesity showing 16.6% average weight loss in trials, expanding options beyond weekly injections.
- On Dec. 22, 2025 the U.S. Food and Drug Administration approved a pill version of Wegovy, Novo Nordisk A/S's first oral GLP-1 therapy cleared for weight management in the United States.
- In the 64-week OASIS 4 trial, 307 adult participants randomized to oral semaglutide 25 mg showed mean weight loss of about 17% when treatment was adhered to.
- Among trial participants, 76% achieved at least 5% weight loss; a 1.5 mg starting dose will be available in early January for $149 per month, and production is underway at Novo Nordisk North Carolina manufacturing sites.
- Novo Nordisk plans a U.S. launch in early January 2026, including an indication to reduce major adverse cardiovascular events, while pricing and demand remain key market factors.
- Facing competition from Eli Lilly, Novo Nordisk struggles to regain share as more patients choose Zepbound, while it argues a convenient GLP-1 pill without cold storage could boost interest but unclear if market share will rise.
300 Articles
300 Articles
Pill Version of Weight-Loss Drug Wegovy Approved by US Regulator
U.S. regulators have green-lit a pill version of the weight-loss drug Wegovy, making an oral version of the so-called “skinny jabs” available for the first time. The Food and Drug Administration approved the pill made by Scandinavian pharmaceutical company Novo Nordisk, giving it the edge over American rival Eli Lilly in the race to bring an anti-obesity pill to market. Lilly manufactures the Mounjaro (Zepbound) drug, while Novo Nordisk makes bo…
Novo Nordisk has received FDA approval for the weight loss pill Wegovy. The pill shows promising results and could significantly affect the lucrative market for weight loss medications.
The European pharmaceutical company Novo Nordisk announced on Tuesday that the U.S. Food and Drug Administration (FDA) has approved the first slimming pill that uses the same active substance as Ozempic and Wegovy , semaglutide, with the same efficacy, but avoiding puncture . The new drug, also called Wegovy , is a pill with 25 mg oral semaglutide , which is taken once a day, to reduce body weight excess, maintain long-term loss and reduce the r…
Coverage Details
Bias Distribution
- 70% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
